2 completed, 1 not yet recruiting, 1 recruiting. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow Fei Li: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Bumetanide in Children With Autism Spectrum Disorder Guided by Peripheral Blood Biomarkers and Machine Learning Models Bumetanide, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 66 | 2025-06-04 | 2026-04-29 |
| Efficacy of Nutritional Supplements on Children With Autism Spectrum Disorder Nutritional supplements, Treatment as usual (TAU) - Autism Spectrum Disorder | Phase 2 | Completed | Fei Li | 88 | 2025-04-01 | 2026-04-23 |
| Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial Orelabrutinib, rituximab, Cyclophosphamide - Marginal Zone Lymphoma(MZL) | Phase 2 | Recruiting | Fei Li | 90 | 2024-12-01 | 2025-06-17 |
| A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi Monotherapy orelabrutinib, FCR/BR, BTK inhibitor - CLL/SLL | Phase 2 | Not yet recruiting | Fei Li | 60 | 2024-07-24 | 2024-06-27 |
Autism Spectrum Disorder (2) · Lymphoma, B-Cell, Marginal Zone (1)
Therapeutics (2) · orelabrutinib (2) · Bumetanide (1) · Cyclophosphamide (1) · Dietary Supplements (1) · Prednisone (1) · Rituximab (1) · Vincristine (1)
China (3)